Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Report | 15 May 2025 HIV/AIDS Research and development South AfricaUnited States of America South Africa’s TB and HIV Research at Risk : A Call To Catalyze Urgent Action By Funders
Photograph by Alexandra Sadokova Press release Press release | 24 April 2025 Transparency Call for transparency: detailed cost analysis of MSF’s TB-PRACTECAL clinical trial in PLOS Global Public Health 2 min
Photo Credit: Vanessa Fodjo/MSF Press release Press release | 15 April 2025 Pandemic preparedness MSF welcomes progress on Pandemic Agreement negotiations: A step toward equity in future pandemics and health emergencies 4 min
UN Photo/Christopher Black Statement Statement | 07 April 2025 Pandemic preparedness WHO Pandemic Agreement: MSF Statement at the INB13 Resumed session 2 min
Photo credit: Thibault Fendler/MSF Press release Press release | 27 March 2025 Vaccines United States of America US decision to end support for Gavi puts millions of children’s lives at risk 3 min
Photo Credit: Stuart Tibaweswa /Epicentre Press release Press release | 19 March 2025 Tuberculosis MSF calls for sustained investments to fight against tuberculosis in children 4 min
Photo Credit: Martim Gray Pereira/MSF Press release Press release | 14 February 2025 HIV/AIDS United States of America Uncertainty around PEPFAR program puts millions of people at risk 6 min
Photo Credit: Mariam Abu Dagga Statement Statement | 06 February 2025 MSF statement on EB156/17 - Health conditions in the occupied Palestinian territory, including east Jerusalem 1 min
